Mr. Facundo Garreton reports

BLUEBERRIES MEDICAL ANNOUNCES CLOSING OF C$1.1 MILLION NON-BROKERED PRIVATE PLACEMENT

Blueberries Medical Corp. has closed a non-brokered private placement consisting of the sale of 84,615,385 common shares at a price of 1.3 cents per common share for aggregate gross proceeds of approximately $1.1-million (or approximately $781,000 (U.S.)). The net proceeds from the sale of the common shares are expected to finance and expand operations, and for general corporate and working capital purposes.

The offering was led by Terraflos Inc., a company with operations throughout Latin America founded and controlled by Facundo Garreton, who serves as the chairman, chief executive officer and a director of Blueberries. Terraflos is an economic group focused on investing in and scaling businesses within the wellness and longevity sectors, leveraging its strategic footprint and industry expertise across Latin America, and is controlled by Mr. Garreton, the chairman, chief executive officer and a director of Blueberries.

Early warning disclosure

Immediately prior to the offering, Mr. Garreton, directly and through Terraflos, owned 308,411,601 common shares and options exercisable into 3,299,500 common shares. If the options were exercised in full, they would result in the issuance of 3,299,500 common shares to Mr. Garreton for aggregate holdings on an as-converted basis of 311,711,101 common shares, representing, on a partially diluted basis, approximately 62.54 per cent of the outstanding common shares prior to the offering. Immediately following the offering, Mr. Garreton owned on an as-converted basis (assuming the exercise the options, directly and through Terraflos) 396,326,486 common shares, representing, on a partially diluted basis, approximately 67.98 per cent of the outstanding common shares.

Mr. Garreton, through Terraflos, acquired the common shares for investment purposes, and he may, depending on market and other conditions, increase or decrease his beneficial ownership, control or direction over additional securities of the securities or otherwise. Other than as noted above and a right to a board seat for so long as Mr. Garreton holds at least 8 per cent of the outstanding common shares on an as-converted basis, Mr. Garreton does not have any plans related to any of the matters in the enumerated list in Item 5.1 of Form 62-103F1.

Mr. Garreton will prepare and file a report containing the information required by Form 62-103F1 (Required Disclosure under the Early Warning Requirements) in connection with the matters referred to in this press release. Once filed, a copy of the early warning report will be available under the company's issuer profile on SEDAR+.

Participation by Terraflos and Mr. Garreton in the offering was considered a related-party transaction pursuant to Multilateral Instrument 61-101 (Protection of Minority Security Holders in Special Transactions). The company was exempt from the requirements to obtain a formal valuation or minority shareholder approval in connection with Terraflos's and Mr. Garreton's participation in the offering in reliance of sections 5.5(b) and 5.7(1)(b) of MI 61-101. A material change report was filed in connection with the participation of Terraflos and Mr. Garreton in the offering fewer than 21 days in advance of the closing of the offering, which the company deemed reasonable in the circumstances so as to be able to avail itself of potential financing opportunities and complete the offering in an expeditious manner.

About Blueberries Medical Corp.

Blueberries is a consumer science company focused on health, wellness and longevity. The company is a licensed producer of both psychoactive and non-psychoactive cannabis derivatives in Colombia. As a key operating entity within Terraflos, a Latin America-based consumer science company that integrates science, biotechnology and artificial-intelligence-driven design, Blueberries contributes to the development of effective, sustainable wellness solutions derived from natural plant compounds.

The company specializes in the scalable production and extraction of high-value bioactives from a diverse array of Latin American botanicals. With strategically located operations and a multidisciplinary team of life science experts, Blueberries plays a critical role in the formulation of standardized, pharmaceutical-grade ingredients used in functional foods, dietary supplements and skin care products. Originating in cannabinoid research, the company has since expanded its capabilities to include a broad portfolio of plant-derived compounds, using both traditional cultivation and advanced extraction technologies.

As an integral part of Terraflos's fully integrated ecosystem, Blueberries supports the transformation of natural bioactives into science-based wellness products. The company emphasizes sustainable sourcing, maintains rigorous production standards and enables the global distribution of innovative botanical solutions.

We seek Safe Harbor.